Product Monograph master template - Canada.ca
Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Drug Product Database; the manufacturer’s website [website], or by calling 1-800-[phone number].
Guidance document: Product Monograph (2020) - Canada.ca
2020年9月10日 · A product monograph is a factual, scientific document on a drug product that, devoid of promotional material, describes the properties, claims, indications, and conditions of use for the drug, and that contains any other information that may be required for optimal, safe, and effective use of the drug.
Product monograph guidance documents and notices - Canada
2020年11月1日 · Notice - Product Monograph Template Revisions: a) New Boxed Message Insert for Overdose Management Information; b) New Address for Canada Vigilance Program [2010-02-17] Notice: Transparency - Release of Product Monographs Directly to Requesters [2006-05-29]
2024年3月12日 · Product Monograph Master Template Template Date: September 2020 Awiqli® (insulin icodec injection) Page 4 of 64 PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS Awiqli® (insulin icodec injection) is indicated for:
Product Monograph Master Template Template Date: September 2020 YERVOY® (ipilimumab for injection) Page 2 of 74 PD-L1 ≥ 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC, when used in combination with nivolumab.
active immunization against smallpox, monkeypox and related orthopoxvirus infection and disease in adults 18 years of age and older determined to be at high risk for exposure. The vaccine may be used for both primary vaccination and revaccination.
Guidance document : product monograph. : H164-299/2020E-PDF
A product monograph is intended to provide the necessary information for the safe and effective use of a new drug and also to serve as a standard against which all promotion and advertising of the drug can be compared.
Refer to the Product Monographs for co-administered trastuzumab and capecitabine for dose modifications for toxicities suspected to be caused by those therapies. 1. Permanently discontinue TUKYSA in patients unable to tolerate 150 mg twice daily. Initiate or …
Product monographs: Frequently asked questions - Canada.ca
2020年11月1日 · The six individual Product Monograph templates: Product Monograph Template - Standard, Product Monograph Template - Notice of Compliance with Conditions, Product Monograph Template - Subsequent Entry Product, Product Monograph Template - Schedule C, Product Monograph Template - Schedule D, and Product Monograph Template - Schedule D ...
Formulary Management Resource Center - ASHP
The ASHP Formulary Management Resource Center aims to assist practitioners with important clinical and operational aspects of formulary management and recommends effective processes for managing system formularies within the context of a hospital or health system.
- 某些结果已被删除